Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol Fumarate Inhalation Solution in COPD (NCT00280371)
NCT00280371Phase 3Completed
- Sponsor
- Dey
- Start
- Jan 2006
- Primary completion
- Jul 2006
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Dey. Primary endpoint: FEV1 Area Under the Curve at 12 weeks. Started Jan 2006; status: completed.
02
Drugs
formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00280371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280371.